Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.44 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932398 | 0.81 | NAMPT (0.55) | NAMPT | |
| SCHEMBL16014433 | 0.80 | RORC (0.46) | NAMPTGPR119NR1H2RORCPIK3CA | |
| SCHEMBL15919201 | 0.78 | MMP1 (0.48) | GPR119NR1H2 | |
| SCHEMBL15919202 | 0.78 | MMP1 (0.48) | GPR119NR1H2 | |
| SCHEMBL15919223 | 0.78 | MMP1 (0.48) | GPR119NR1H2 | |
| SCHEMBL21798300 | 0.77 | GPR119 (0.50) | NAMPTGPR119RORCPIK3CAAKT1 | |
| SCHEMBL21761060 | 0.77 | PDE4B (0.47) | STSUSP30 | |
| SCHEMBL26966945 | 0.76 | GPR119 (0.47) | NAMPTGPR119PIK3CAAKT1MTOR | |
| SCHEMBL26961007 | 0.76 | RORC (0.47) | NAMPTGPR119NR1H2RORCSTS | |
| SCHEMBL25520170 | 0.75 | CA1 (0.46) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | RBP4 4669/4885NAMPT 2101/4885GPR119 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.